Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TCMD vs VTAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TCMD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

TCMD Overall Winner 6-Pillar Tally: TCMD 5 – 1 VTAK Matrix Metrics: TCMD 8 – 2 VTAK

As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TCMD carries a Unified Composite Score of 25.2/100 (SELL) at $26.37 (17.9x Forward P/E, 9.4% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin).

  • Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. TCMD 25.2/100 SELL), TCMD captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -388.1% operating margin) and revenue trajectory (+7.1% vs. +380.7% YoY).
  • Technical & Structure Timing Caution: TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.7); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TCMD vs VTAK
TCMD NASDAQ Head-to-Head Winner
Tactile Systems Technology, Inc.
Surgical & Medical Instruments & Apparatus
$26.37
-1.64% 1D
Market Cap $600.6M
TTM Revenue $356M
Forward P/E 17.9x
Beta / 30D Vol 1.07β · 53% Vol
Unified Composite Score
25.2 / 100 SELL
Tech 50.0 Fund 28.0 Flow 66.0 Mom 21.4
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.3% over 20 days), RSI 61
RSI-14: 60.7 · SMA20: $24.98 · SMA50: $23.45
VTAK NYSE American
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21

6-Pillar Scorecard Institutional Category Breakdown (TCMD 5 – 1 VTAK)

Columns: Metric · TCMD · VTAK
1. Valuation Multiples TCMD
Forward P/E 17.9x N/M
Trailing P/E 26.0x N/M
PEG Ratio 17.79x N/M
EV / Revenue 1.5x 0.3x
2. Growth & Scale VTAK
Revenue Growth (YoY) +7.1% +380.7%
Earnings Growth (YoY) -13.9% +0.0%
TTM Revenue (USD) $356M $1.9M
Market Cap $600.6M $548,639
3. Profitability & Quality TCMD
Gross Margin 77.0% 47.7%
Operating Margin 9.4% -388.1%
Net Profit Margin 6.7% 0.0%
Return on Equity (ROE) 11.0% -111.3%
4. Balance Sheet & Cash Flow TCMD
Cash Generation (TTM) $29M -$10M EBITDA
Cash Flow Margin 8.1% N/A
Net Cash / Leverage $58M Net Cash $4.87 Book/Sh · -111.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TCMD
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 54.9% (15th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat TCMD
OpEx & R&D Intensity 67.6% of Rev ($241M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TCMD (8) vs VTAK (2)
Institutional Metric TCMD VTAK Criterion Row Edge
Market Capitalization
Scale
$600.6M $548,639 Larger Scale TCMD
Trailing P/E Ratio
Valuation
26.0x N/M Lower Multiple TCMD
Forward P/E Ratio
Valuation
17.9x N/M Lower Multiple TCMD
Revenue Growth (YoY)
Growth
+7.1% +380.7% Higher Growth VTAK
Operating Margin (TTM)
Profitability
9.4% -388.1% Higher Margin TCMD
Net Profit Margin
Profitability
6.7% 0.0% Higher Margin TCMD
Return on Equity (ROE)
Capital Efficiency
11.0% -111.3% Higher ROE TCMD
52-Week Range Position
Momentum
34% ($21–$38) 1% ($0–$3) Stronger Trend TCMD
Beta / 30D Volatility
Risk Regime
1.07β · 53% Vol 0.19β · 76% Vol Lower Realized Risk TCMD
Unified Institutional Score
Composite Signal
25.2 / 100 (SELL) 58.1 / 100 (HOLD) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$356M $1.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.0% 47.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
17.79x PEG · 1.5x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$29M ($58M Net Cash) -$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TCMD +23.38 pp
TCMD: -1.38% · VTAK: -24.76%
3M Horizon TCMD +49.63 pp
TCMD: -30.66% · VTAK: -80.29%
6M Horizon TCMD +73.6 pp
TCMD: -10.16% · VTAK: -83.76%
1Y Horizon TCMD +83.32 pp
TCMD: -9.31% · VTAK: -92.63%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period TCMD Revenue VTAK Revenue TCMD Op. Margin VTAK Op. Margin Margin Leader
FY2018 $140M $10M 2.1% -498.0% TCMD
FY2019 $190M $10M 5.5% -801.9% TCMD
FY2020 $190M $0M -1.9% -13668.3% TCMD
FY2021 $210M $0M -0.8% -133027.3% TCMD
FY2022 $250M $0M -5.2% -192578.6% TCMD
FY2023 $270M $0M 6.6% -17674.0% TCMD
FY2024 $290M $0M 7.6% -2676.9% TCMD
FY2025 $330M $0M 8.9% -2581.6% TCMD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TCMD CONSOLIDATION
94d in phase · OBV ACCUMULATION
Current IV 54.9%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact TCMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TCMD Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $600.6M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment 67.6% of Rev ($241M)
90D Engineering Disclosures 0 Published
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TCMD vs VTAK Key Questions & Quantitative Answers

As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TCMD carries a Unified Composite Score of 25.2/100 (SELL) at $26.37 (17.9x Forward P/E, 9.4% operating margin), whereas VTAK carries 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin). Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. TCMD 25.2/100 SELL), TCMD captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -388.1% operating margin) and revenue trajectory (+7.1% vs. +380.7% YoY). Technical & Structure Timing Caution: TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.7); meanwhile VTAK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTAK leads the Growth & Scale pillar: TCMD posts +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin), compared with VTAK at +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), TCMD cumulative revenue shifted +135.7% while VTAK shifted +0.0%. In operating R&D and SG&A reinvestment, TCMD deploys 67.6% of Rev ($241M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTAK.

TCMD screens cheaper on headline valuation multiples. TCMD trades at 17.9x Forward P/E, 26.0x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin), whereas VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TCMD (11.0% ROE) versus VTAK (-111.3% ROE) capital efficiency.

In options market volatility and institutional positioning, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 53% Vol realized risk). By comparison, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.